Welcome to our dedicated page for INVO Fertility news (Ticker: IVF), a resource for investors and traders seeking the latest updates and insights on INVO Fertility stock.
INVO Fertility, Inc. operates as a healthcare services fertility company focused on assisted reproductive technology care through the establishment, acquisition and operation of fertility clinics and related technologies. Company news commonly covers clinic expansion, acquired fertility practices, network relationships, laboratory capabilities and the use of the INVOcell medical device for intravaginal culture procedures.
Recurring updates also include intellectual-property developments for INVOcell, operational changes at U.S. fertility clinics, capital-structure actions such as reverse stock splits, shareholder communications, securities-listing compliance matters and financial-reporting status. Recent company materials also identify Family Beginnings and Wisconsin Fertility Institute as part of the clinic platform.
INVO Fertility (NASDAQ:IVF) reported its Q2 2025 financial results, achieving record quarterly revenue of $1.86 million, up 1% year-over-year. The company's consolidated clinic revenue from Atlanta and Madison locations increased 1% to $1.83 million, while total revenue including equity method clinics rose 2% to $2.19 million.
Key operational highlights include Wisconsin Fertility Institute's recognition on Newsweek's Best Fertility Clinics list, launch of telehealth capabilities, and addition of Platelet-Rich Plasma therapy services. The company received a patent allowance for its modified INVOcell device, extending protection through 2040. INVO completed the divestiture of NAYA Therapeutics, retaining a minority stake while refocusing on core fertility operations.
However, the company reported a net loss from continuing operations of $(3.2) million, compared to $(2.2) million in Q2 2024, with Adjusted EBITDA at $(587,230).
INVO Fertility (NASDAQ: IVF) has announced a 1-for-3 reverse stock split effective July 21, 2025, at 12:01 a.m. Eastern Time. The company's common stock will continue trading under the symbol "IVF" on the Nasdaq Capital Market with a new CUSIP number 44984F708.
Following the split, every 3 shares will be consolidated into 1 share, with fractional shares rounded up. The company's outstanding shares will decrease to approximately 928,272, and authorized shares will be adjusted to 1,388,888. The primary goal is to meet Nasdaq's minimum bid price requirement of $1.00 per share for continued listing, though compliance is not guaranteed.
INVO Fertility (NASDAQ: IVF) announced strategic enhancements to its INVOcell® technology program, including expanded clinical training support and improved pricing. INVOcell, the first FDA-cleared intravaginal culture system, offers a more natural fertility treatment alternative to traditional IVF with comparable pregnancy rates.
The company is strengthening its dual position as both a technology innovator and fertility clinic operator. Key features of INVOcell include using the woman's body as a natural incubator, demonstrated success rates comparable to conventional IVF, and increased accessibility for diverse family structures. The technology recently secured a new U.S. patent allowance and offers clinics improved operational efficiency.
INVO Fertility (Nasdaq: IVF) has announced the addition of Platelet-Rich Plasma (PRP) therapy to its fertility services at the Wisconsin Fertility Institute center. The treatment utilizes the body's own growth factors to stimulate uterine lining growth and ovarian rejuvenation, potentially improving implantation rates and ovarian response.
The therapy is specifically designed for women facing particular fertility challenges, including those with thin uterine lining, diminished ovarian reserve, and patients seeking alternatives before considering egg donation or surrogacy. Dr. Gretchen Collins, a double board certified OB/GYN and REI at Wisconsin Fertility Institute, notes that while PRP therapy remains experimental in fertility treatment, it has demonstrated success in other medical fields such as orthopedics and wound healing.
INVO Fertility (Nasdaq: IVF) has received a notice of allowance for a new patent extending protection of its modified INVOcell device through 2040. The patent (Application No. 16/949,960) covers a simplified design based on embryologist feedback, removing the separate microchamber in favor of a singular main chamber.
INVOcell is the world's first FDA-cleared intravaginal culture (IVC) system that enables fertilization and embryo development within a woman's body. The device, which delivers comparable pregnancy rates to traditional IVF, was first FDA-cleared in 2015 and received additional clearance in 2023 for an extended 5-day incubation period.
INVO Fertility (NASDAQ: IVF), a healthcare services company focused on expanding access to advanced fertility treatments, has announced its participation in the upcoming Lytham Partners Spring 2025 Investor Conference on May 29, 2025. The company will engage in a virtual webcast fireside chat at 4:15 p.m. ET and conduct one-on-one meetings with investors throughout the event.
The webcast will be accessible through the conference homepage and will be available for replay after the event. Investors interested in one-on-one meetings with management can arrange them through Lytham Partners or by registering for the event directly on their website.